Linnea SA

Linnea has been a pioneering pharmaceutical manufacturer of high-quality botanical ingredients for over 40 years, distinguishing itself through expertise, quality, and innovation. Since its founding in 1982, Linnea has focused on developing top-tier plant-based APIs at its GMP-certified facility in Switzerland. Known for its dedication to excellence, Linnea ensures every ingredient adheres to rigorous standards, with a particular emphasis on GACP compliance. As of 2014, the company has expanded its focus to cannabinoid research and development, launching its first cannabinoid ingredient in 2016. This marked the beginning of our commitment to applying the same science-based, uncompromising approach to the pharmaceutical manufacturing of cannabinoids for customers worldwide. Looking ahead, Linnea is poised to strengthen its operations with a new state-of-the-art manufacturing plant dedicated exclusively to medical cannabis derivatives. This positions the company as one of the very few industry leaders devoted to the highest levels of quality, ensuring sustained growth and cutting-edge advancements in the cannabinoid market through 2025 and beyond.

At Linnea, we recognize the immense potential for transformational growth in Europe’s cannabis industry. We are excited to share our commitment to clinical excellence, innovation, and sustainable practices that drive the future of cannabinoid manufacturing. With our state-of-the-art facilities and unwavering dedication to quality, we are proud to play an active role in shaping Europe’s cannabis landscape, contributing to setting new benchmarks for industry standards on a global scale.